Placebo Effect in Field-Based Physical Performance
NCT07742150, Not applicable, Not yet recruiting, Poznan University of Physical Education
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Placebo Effect in Field-Based Physical Performance | ClinicalTrials.gov |
| NCT number | NCT07742150 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Poznan University of Physical Education | ClinicalTrials.gov |
| Conditions | Physical Performance, Placebo Effect, Cognitive Performance | ClinicalTrials.gov |
| Interventions | Caffeine (6mg/kg), Placebo (Starch capsule), Sham (No Treatment) | ClinicalTrials.gov |
| First posted | 2026-08-03 | ClinicalTrials.gov |
| Last updated | 2026-08-03 | ClinicalTrials.gov |
Registered outcomes 22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Physical Performance Capacity (total distance in running, metres) | Measured during the exercise protocol immediately following administration of the study intervention. | Total physical work capacity measured as the total running distance (metres) completed during the standardized exercise protocol. | ClinicalTrials.gov |
| Primary | Physical Performance Capacity (total work in Joules for cycling) | Measured during the exercise protocol immediately following administration of the study intervention. | Total physical work capacity measured as the total mechanical work (Joules) completed during the standardized cycling exercise protocol. | ClinicalTrials.gov |
| Primary | Physical Performance Capacity (exercise duration until exhaustion, minutes) | Measured during the exercise protocol immediately following administration of the study intervention. | Total physical work capacity measured as exercise duration until volitional exhaustion during the standardized exercise protocol. | ClinicalTrials.gov |
| Secondary | Exercise Heart Rate (bpm) | Continuously monitored during the exercise protocol immediately following administration of the study intervention. | Heart rate (beats per minute) recorded continuously throughout the standardized exercise protocol. | ClinicalTrials.gov |
| Secondary | Cognitive Heart Rate (bpm) | Measured during cognitive testing immediately before and immediately after the exercise protocol. | Heart rate recorded during standardized cognitive performance tasks. | ClinicalTrials.gov |
| Secondary | Post-Exercise Heart Rate Recovery (bpm) | Continuously monitored during the first 5 minutes immediately following completion of the exercise protocol. | Heart rate recorded during the post-exercise recovery period. | ClinicalTrials.gov |
| Secondary | Cognitive Reaction Time (ms) | Measured immediately before and immediately after the exercise protocol. | Reaction time measured during standardized cognitive tasks (e.g., Psychomotor Vigilance Test, Stroop Test, Flanker Test). | ClinicalTrials.gov |
| Secondary | Rating of Perceived Exertion (Borg Scale, points) | Measured immediately after completion of the exercise protocol. | Perceived exertion assessed using the Borg Rating of Perceived Exertion Scale (6-20). | ClinicalTrials.gov |
| Secondary | Biomechanical Kinematic Profile (cm) | Continuously monitored during the exercise protocol immediately following administration of the study intervention. | Continuous recording of kinematic parameters derived from wearable sensors, including step length and vertical oscillation. | ClinicalTrials.gov |
| Secondary | Biomechanical Kinematic Profile (ms) | Continuously monitored during the exercise protocol immediately following administration of the study intervention. | Continuous recording of stance time derived from wearable sensor data. | ClinicalTrials.gov |
| Secondary | Biomechanical Kinematic Profile (steps/min) | Continuously monitored during the exercise protocol immediately following administration of the study intervention. | Continuous recording of cadence derived from wearable sensor data. | ClinicalTrials.gov |
| Secondary | Anthropometric Indices (kg) | Measured at the start of the protocol. | Body mass expressed in kilograms. | ClinicalTrials.gov |
| Secondary | Anthropometric Indices (m) | Measured at the start of the protocol. | Height expressed in metres. | ClinicalTrials.gov |
| Secondary | Body composition (fat-free mass, fat mass) (kg) | Measured at the start of the protocol. | Assessment of body composition (fat-free mass, fat mass) (kg) will be performed at the start of the protocol. | ClinicalTrials.gov |
| Secondary | Body composition (fat-free mass, fat mass) (%) | Measured at the start of the protocol. | Assessment of body composition (fat-free mass, fat mass) (%) will be performed at the start of the protocol. | ClinicalTrials.gov |
| Secondary | Body composition (total body water) (L) | Measured at the start of the protocol. | Assessment of body composition (total body water) (L) will be performed at baseline at the start of the protocol. | ClinicalTrials.gov |
| Secondary | Body composition (total body water) (%) | Measured at the start of the protocol. | Assessment of body composition (total body water) (%) will be performed at baseline at the start of the protocol. | ClinicalTrials.gov |
| Secondary | Exercise Heart Rate Variability (ms) | Continuously monitored during the exercise protocol immediately following administration of the study intervention. | Heart rate variability recorded continuously throughout the standardized exercise protocol to assess autonomic regulation. | ClinicalTrials.gov |
| Secondary | Cognitive Heart Rate Variability (ms) | Measured during cognitive testing immediately before and immediately after the exercise protocol. | Heart rate variability recorded during standardized cognitive performance tasks. | ClinicalTrials.gov |
| Secondary | Post-Exercise Heart Rate Variability Recovery (ms) | Continuously monitored during the first 5 minutes immediately following completion of the exercise protocol. | Heart rate variability recorded during the post-exercise recovery period. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Eriksen Flanker Task | Secondary outcome | ConductCognition |
| Psychomotor Vigilance Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)